摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(4-methylcyclohexyl)propanoic acid | 324795-76-8

中文名称
——
中文别名
——
英文名称
3-(4-methylcyclohexyl)propanoic acid
英文别名
3-(4-Methyl-cyclohexyl)-propionic Acid;3-((1r,4r)-4-Methylcyclohexyl)propanoic acid
3-(4-methylcyclohexyl)propanoic acid化学式
CAS
324795-76-8
化学式
C10H18O2
mdl
——
分子量
170.252
InChiKey
PRDNSPVJDDSZGL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    12
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.9
  • 拓扑面积:
    37.3
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    3-(4-methylcyclohexyl)propanoic acid氯化亚砜 作用下, 以92.03 %的产率得到3-(4-methylcyclohexyl)propanoyl chloride
    参考文献:
    名称:
    [EN] IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY
    [FR] LIPIDES CATIONIQUES IONISABLES POUR L'ACHEMINEMENT D'ARN
    摘要:
    本公开说明书描述了公式(I)的化合物及其药学上可接受的盐。
    公开号:
    WO2023086514A1
点击查看最新优质反应信息

文献信息

  • Novel succinate derivative compounds useful as cysteine protease inhibitors
    申请人:——
    公开号:US20010041700A1
    公开(公告)日:2001-11-15
    Disclosed are novel succinate derivative compounds of the formula (I)/(Ia): 1 wherein R1, R2, R3, R4, R5, R6, R7, X and A are defined herein. The compounds are useful as inhibitors of cysteine proteases. Also disclosed are methods of using and methods of making such compounds.
    披露了新型琥珀酸生物化合物,其化学公式为(I)/(Ia):1,其中R1、R2、R3、R4、R5、R6、R7、X和A的定义如下。这些化合物可用作胱蛋白酶抑制剂。还披露了使用和制造这些化合物的方法。
  • [EN] INHIBITORS OF INFLUENZA VIRUSES REPLICATION<br/>[FR] INHIBITEURS DE LA RÉPLICATION DES VIRUS DE LA GRIPPE
    申请人:VERTEX PHARMA
    公开号:WO2012083117A1
    公开(公告)日:2012-06-21
    Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.
    抑制流感病毒在生物样本或患者中复制的方法,减少生物样本或患者中流感病毒的数量,以及治疗患者的流感,包括向所述生物样本或患者投与结构式(I)所代表的化合物的有效量或其药学上可接受的盐,其中结构式(I)的值如本文所述。一种化合物由结构式(I)或其药学上可接受的盐所代表,其中结构式(I)的值如本文所述。一种药物组合物包括这种化合物或其药学上可接受的盐的有效量,以及药学上可接受的载体、辅料或溶剂。
  • NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS
    申请人:Boehringer Ingelheim Pharmaceuticals, Inc.
    公开号:US20030087939A1
    公开(公告)日:2003-05-08
    Disclosed are novel succinate derivative compounds of the formula (I)/(Ia): 1 wherein R1, R2, R3, R4, R5, R6, R7, X and A are defined herein. The compounds are useful as inhibitors of cysteine proteases. Also disclosed are methods of using and methods of making such compounds.
    本发明公开了一类新型琥珀酸生物化合物,其化学式为(I)/(Ia):1,其中R1、R2、R3、R4、R5、R6、R7、X和A的定义如本文所述。这些化合物可用作半胱蛋白酶抑制剂。本发明还公开了使用这些化合物的方法和制备这些化合物的方法。
  • PD-L1 ANTAGONIST COMPOUND
    申请人:Adlai Nortye Biopharma Co., Ltd.
    公开号:EP4083032A1
    公开(公告)日:2022-11-02
    Provided are a compound of Formula (I) and a pharmaceutical composition thereof, as well as a method for using the compounds of Formula (I) to prevent and/or treat immune-related disorders.
    提供了化合物(I)及其制药组合物,以及使用化合物(I)预防和/或治疗免疫相关疾病的方法。
  • Heteroaryl amide derivatives
    申请人:H. Lundbeck A/S
    公开号:EP2591675A1
    公开(公告)日:2013-05-15
    Heteroaryl amide derivatives suitable as P2X7 receptor antagonists of the following Formula are provided. The compounds can be applied in the treatment of pain, inflammation, a neurological or neurodegenerative disorder, a centrally-mediated neuropsychiatric disorder, a cardiovascular disorder or an immune system disorder.
    提供了适合作为 P2X7 受体拮抗剂的下式杂芳基酰胺衍生物。 这些化合物可用于治疗疼痛、炎症、神经或神经退行性疾病、中枢介导的神经精神疾病、心血管疾病或免疫系统疾病。
查看更多